OA drug Prexige faces snub by FDA: "The future doesn't look good for Novartis' COX-2 selective inhibitor Prexige.
In late September, the Swiss pharmaceutical company received a 'not approvable' letter from the FDA in response to its application for the product's use as a once-daily treatment for osteoarthritis pain. This was followed days later by the removal of Prexige from the Canadian market, after Health Canada's request that the company cease sales and marketing of the product."